CVS Health Aktie
WKN: 859034 / ISIN: US1266501006
13.01.2017 08:07:18
|
CVS Offering Cheap Generic Alternative To EpiPen
(RTTNews) - CVS Health Corp., the nation's largest drug-store chain, announced Thursday a cheap generic alternative to Mylan's Epipen auto-injector for life-threatening allergies. CVS has joined with Impax Laboratories to offer the generic epinephrine auto-injector at cash price 80% lower than EpiPen.
The less-expensive epinephrine auto-injector, an authorized generic for Adrenaclick manufactured by Impax, is available at a cash price of $109.99 for a two-pack, the lowest cash price in the market, the company noted. This is compared to a two-pack price of $649.99 for Epipen and $339.99 for the authorized generic for EpiPen.
CVS said the authorized generic for Adrenaclick is a Food and Drug Administration -approved device with the same active ingredient as other epinephrine auto-injector devices.
The critical lifesaving medication is available starting Thursday nationwide in the company's more than 9,600 pharmacies.
Helena Foulkes, President of CVS Pharmacy, said, "...we recognized that there was an urgent need in the marketplace for a less expensive epinephrine auto-injector for patients with life-threatening allergies."
The company noted that nearly 150,000 people signed on to a petition last year asking for a lower cost epinephrine auto-injector option.
Mylan has been facing a widespread outrage from lawmakers and the public after the company implemented sharp price increases for EpiPen to over $600 from about $100 in 2008 after it acquired the product in 2007. Mylan in December last year launched its authorized generic for EpiPen for half the price.
President-elect Donald Trump on Wednesday had made fresh attacks over skyrocketing drug costs.
Cary Sennett, President and CEO of the Asthma and Allergy Foundation of America, said, "We're encouraged to see national efforts to make epinephrine auto-injectors more affordable and more available to Americans across the country. Partnerships that increase access to vital medications are key in helping those suffering from life-threatening allergies."

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu CVS Health Corpmehr Nachrichten
25.04.25 |
S&P 500-Titel CVS Health-Aktie: So viel Verlust hätte ein CVS Health-Investment von vor einem Jahr eingefahren (finanzen.at) | |
18.04.25 |
S&P 500-Titel CVS Health-Aktie: So viel hätten Anleger an einem CVS Health-Investment von vor 10 Jahren verloren (finanzen.at) | |
17.04.25 |
Börse New York: S&P 500 zum Start des Donnerstagshandels fester (finanzen.at) | |
16.04.25 |
Erste Schätzungen: CVS Health gewährt Anlegern Blick in die Bücher (finanzen.net) | |
11.04.25 |
S&P 500-Titel CVS Health-Aktie: So viel Gewinn hätte ein Investment in CVS Health von vor 5 Jahren eingefahren (finanzen.at) | |
08.04.25 |
Schwacher Wochentag in New York: S&P 500 fällt zum Handelsende zurück (finanzen.at) | |
08.04.25 |
Optimismus in New York: S&P 500 notiert im Plus (finanzen.at) | |
08.04.25 |
Dienstagshandel in New York: S&P 500-Anleger greifen am Dienstagmittag zu (finanzen.at) |
Analysen zu IMPAX Laboratories Inc.mehr Analysen
Aktien in diesem Artikel
CVS Health Corp | 57,48 | 0,23% |
|